Evaluation of treatment response by Hopkins criteria on18F FDG PET-CT in patients of non-small cell lung cancer and its comparison with PERCIST response criteria

被引:0
|
作者
Dang, Shreya [1 ]
Shivdasani, Divya [1 ]
Pereira, Melvika [1 ]
Singh, Natasha [1 ]
Rungta, Rachita [1 ]
Roy, Debdip [1 ]
Kesariya, Jugal [1 ]
机构
[1] PD Hinduja Natl Hosp & Med Res Ctr, Dept Nucl Med & PET CT, Veer Savarkar Marg, Mumbai 400016, India
关键词
evaluation; FDG PET; Hopkins; NSCLC; PERCIST; response; POSITRON-EMISSION-TOMOGRAPHY;
D O I
10.1097/MNM.0000000000001756
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim To assess treatment response on FDG PET-CT in NSCLC patients by visual Hopkins score compared to PERCIST criteria and its potential for prognostication (or its correlation with survival).Methods Forty-four NSCLC patients with baseline and post-treatment FDG PET-CT scans were included, and interpreted using Hopkins and PERCIST criteria classifying patients into responders and non-responders. PERCIST-based CMR and PMR, and Hopkins Scores 1,2,3 were classified responders. PERCIST-based SD and PD and Hopkins scores 4,5 were classified as non-responders. Patients were followed upto 24 months after treatment completion. Cohen kappa for inter-criteria agreement and Kaplan Meir curve for overall survival (OS) analysis done.Results Out of 44 patients, PERCIST classified 27 (61.3%) as responders and 17 (38.6%) as non-responders, whereas Hopkins classified 12 patients (27.3%) as responders and 32 (72.7%) as non-responders. Inter-criteria agreement was low (kappa=0.19) with discordance in 45.5% of patients. Eighteen of 20 discordant cases were non-responders on Hopkins and responders on PERCIST, of which 88.8% were non-responders on follow-up as predicted by Hopkins. PERCIST responders had OS of 96.4% and 64.3% at 9 and 24 months, respectively, while non-responders OS was 93.5% and 40.2% at 9 and 24 months, respectively (P-value = 0.049). However, responders on Hopkins had OS of 100% at 24 months, whereas non-responders had OS of 93.5% and 51.5% at 9 and 24 months, respectively (P-value = 0.232).Conclusion Semi-quantitative PERCIST and visual Hopkins criteria show low inter-criteria agreement, with visual criteria better-predicting survival in patients of NSCLC.
引用
收藏
页码:1038 / 1045
页数:8
相关论文
共 50 条
  • [41] Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer
    Kirchner, J.
    Sawicki, L. M.
    Schaarschmidt, B. M.
    Umutlu, L.
    Herrmann, K.
    Buchbender, C.
    Antoch, G.
    Heusch, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S502 - S502
  • [42] Metabolic response assessment with F-18-FDG PET/CT: inter-method comparison and prognostic significance for patients with non-small cell lung cancer
    Wang, Jingbo
    Wong, Ka Kit
    Piert, Morand
    Stanton, Paul
    Frey, Kirk A.
    Kong, Feng-Ming
    JOURNAL OF RADIATION ONCOLOGY, 2015, 4 (03) : 249 - 256
  • [43] Tumor heterogeneity on 18F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib
    van Gool, Matthijs H.
    Aukema, Tjeerd S.
    Sinaasappel, Michiel
    Olmos, Renato A. Valdes
    Klomp, Houke M.
    JOURNAL OF THORACIC DISEASE, 2016, 8 (03) : E200 - E203
  • [44] Role of texture parameters evaluated from F18-FDG PET/CT in treatment response assessment of Non-Small cell lung cancer
    Kumar, Rakesh
    Sharma, Akshima
    Vishali
    Mohan, Anant
    Bhalla, Ashu
    Vishnubhatla, Sreenivas
    Das, Chandan
    Patel, Chetan
    Bal, Chandrasekhar
    Pandey, Anil
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [45] Comparison of 18F-FDG PET/CT and MDCT for staging/restaging of non-small cell lung cancer
    Sobic-Saranovic, D.
    Petrusic, I.
    Artiko, V.
    Pavlovic, S.
    Subotic, D.
    Saranovic, D.
    Nagorni-Obradovic, L.
    Petrovic, N.
    Todorovic-Tirnanic, M.
    Odalovic, S.
    Grozdic-Milojevic, I.
    Stoiljkovic, M.
    Obradovic, V.
    NEOPLASMA, 2015, 62 (02) : 295 - 301
  • [46] Comparison of 18F-FDG PET/CT and MDCT for Detection Metastases of Non-Small Cell Lung Cancer
    Sobic-Saranovic, D.
    Petrusic, I.
    Artiko, V.
    Kozarevic, N.
    Odalovic, S.
    Grozdic-Milojevic, I.
    Stoiljkovic, M.
    Obradovic, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S485 - S485
  • [47] Is 18F-FDG PET/CT Useful for the Early Prediction of Histopathologic Response to Neoadjuvant Erlotinib in Patients with Non-Small Cell Lung Cancer?
    Aukema, Tjeerd S.
    Kappers, Ingrid
    Olmos, Renato A. Valdes
    Codrington, Henk E.
    van Tinteren, Harm
    van Pel, Renee
    Klomp, Houke M.
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (09) : 1344 - 1348
  • [48] Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab
    Skougaard, Kristin
    Nielsen, Dorte
    Jensen, Benny Vittrup
    Hendel, Helle Westergren
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (07) : 1026 - 1031
  • [49] Treatment response evaluation using F18-FDG PET-CT in patients with metastatic/recurrent breast cancer
    Jeph, Sunil
    Kumar, Rakesh
    Bal, C.
    Malhotra, Arun
    Singh, Harmandeep
    Nazar, Aftab
    Kundu, Parveen
    Kumar, Rajender
    Singla, Suhas
    Karunanithi, Sellam
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [50] Physiologic Colonic Uptake of 18F-FDG on PET/CT Predicts Immunotherapy Response in Patients with Advanced Non-small Cell Lung Cancer
    Regis, Claudine
    Cvetkovic, Lena
    Leblond, Antoine
    Malo, Julie
    Meriem, Messaoudene
    Belkaid, Wiam
    Routy, Bertrand
    Juneau, Daniel
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61